前哨淋巴结活检在不典型子宫内膜增生中的临床效用:多中心队列研究
这项多中心回顾性研究纳入411例术前诊断为不典型子宫内膜增生/子宫内膜上皮内瘤变(AEH/EIN)并接受全子宫切除术的患者,比较行与未行前哨淋巴结(SLN)活检的结局。最终病理确诊隐匿性子宫内膜癌者占47%,其中16%为中高危;SLN转移率为4.7%。SLN评估使SLN队列中22例接受辅助治疗者中的11例(50%)治疗决策发生改变。结论认为SLN活检可行且安全,其状态可细化风险分层并指导辅助治疗的升降级。
要点
- AEH/EIN术前诊断者中47%最终病理为隐匿性子宫内膜癌,其中16%为中高危。
- SLN转移见于4.7%的子宫内膜癌患者,SLN活检仅轻度延长手术时间。
- SLN状态使50%接受辅助治疗者的决策改变,支持在AEH/EIN中考虑SLN活检。
核心结论
- 在AEH/EIN患者中,SLN活检是可行且安全的手术,可为隐匿性子宫内膜癌亚组提供分期信息。
- 无论SLN转移频率如何,SLN状态均提供可操作的预后信息,可细化风险分层并可能指导辅助治疗的升级或降级。
研究设计与样本
- 多中心回顾性研究,纳入2014年至2025年间术前诊断为AEH/EIN并接受全子宫切除术的411例患者。
- 从前瞻性维护的数据库中收集人口学、术前、手术、病理及辅助治疗数据,比较行与未行SLN活检者的结局,采用描述性统计。
主要发现
- 最终病理确诊隐匿性子宫内膜癌者占全部患者的47%,其中16%被归类为中高危病例。
- SLN示踪与手术时间轻度延长相关。
- 在子宫内膜癌患者中,SLN转移率为4.7%。
- 在SLN队列中,22例接受辅助治疗的患者中有11例(50%)的治疗决策因SLN评估而改变。
- SLN阳性导致5例患者化疗升级,SLN阴性支持6例中高危病例省略化疗;非SLN组无患者接受化疗。
临床怎么用
- 对术前诊断为AEH/EIN拟行全子宫切除术的患者,可考虑行SLN活检以获取隐匿性子宫内膜癌的分期信息。
- SLN阳性可支持辅助化疗升级,SLN阴性可支持中高危患者省略化疗,从而细化辅助治疗决策。
局限性
- 本研究为多中心回顾性研究,采用描述性统计,未报告组间比较的统计检验结果。
- 原文未报告非SLN组与SLN组在基线特征上的差异及混杂控制方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the clinical impact of Sentinel Lymph Node (SLN) biopsy in women with preoperative diagnosis of Atypical Endometrial Hyperplasia/Endometrial Intraepithelial Neoplasia (AEH/EIN), focusing on surgical safety and feasibility and adjuvant treatment decisions. METHODS: Multicenter retrospective study which included 411 patients with preoperative diagnosis of AEH/EIN who underwent total hysterectomy between 2014 and 2025. Demographic, preoperative, surgical, pathological and adjuvant treatment data were collected from prospectively maintained databases and outcomes were compared between patients who underwent SLN biopsy and those who did not. Descriptive statistics were used. RESULTS: Occult endometrial cancer (EC) was diagnosed in 47% of overall patients at final pathology; of whom 16% was classified within the intermediate to high-risk cases. SLN mapping was associated with slightly longer operative time. SLN metastases were found in 4.7% of patients with EC. SLN assessment modified treatment decisions in 11 of 22 patients (50%) receiving adjuvant therapy within the SLN cohort. Positive SLN findings led to chemotherapy escalation in 5 patients, while negative SLN status supported chemotherapy omission in 6 high to intermediate risk cases. No patients in the non-SLN group received chemotherapy. CONCLUSION: SLN biopsy in AEH/EIN is a feasible and safe procedure that provides staging information in the subgroup with occult EC. Regardless of metastasis frequency, SLN status provides actionable prognostic information. Whether positive or negative, SLN findings refine risk stratification and may guide the escalation or de-escalation of adjuvant therapy, supporting the consideration of SLN biopsy in AEH/EIN patients.
引用
- Catozzo A, Garzon S, Renso M, et al. Clinical utility of sentinel lymph node biopsy in atypical endometrial hyperplasia: A multicenter cohort study. Gynecol Oncol. 2026. PMID: 42462287. doi:10.1016/j.ygyno.2026.06.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。